Skip to main content
. 2016 Jan 15;8(1):81–97.

Figure 3.

Figure 3

Kaplan-Meier survival curves of 78 patients with EGFR wild-type lung adenocarcinoma according to the immunoreactivity results for aromatase and ERβ. A. Overall survival (OS) stratified by high versus low expression of aromatase. B. Recurrence-free survival (RFS) stratified by high versus low expression of aromatase. C. OS stratified by positive versus negative expression of ERβ. D. RFS stratified by positive versus negative expression of ERβ. E. OS stratified by combined high expression of aromatase/positive expression of ERβ versus combined low expression of aromatase/negative expression of ERβ versus others. F. RFS stratified by combined high expression of aromatase/positive expression of ERβ versus combined low expression of aromatase/negative expression of ERβ versus others.